Article
Neurosciences
Yasuteru Inoue, Teruaki Masuda, Yohei Misumi, Yukio Ando, Mitsuharu Ueda
Summary: The study showed that metformin significantly reduced cerebral amyloid beta deposits in mice and increased levels of IDE, suggesting a potential therapeutic effect in cerebral amyloid angiopathy treatment.
NEUROSCIENCE LETTERS
(2021)
Article
Clinical Neurology
Shahram Oveisgharan, Lei Yu, Ana Capuano, Zoe Arvanitakis, Lisa L. Barnes, Julie A. Schneider, David A. Bennett, Aron S. Buchman
Summary: The study found that a higher cardiovascular Framingham risk score (FRS) in older adults is associated with higher odds of some cerebrovascular disease (CVD) pathologies, but with low discrimination at the individual level. Further work is needed to develop a more robust risk score to identify adults at risk for accumulating CVD pathologies.
Review
Neurosciences
Benedetta Storti, Maria Magdalena Gabriel, Stefan Sennfaelt, Isabella Canavero, Nicola Rifino, Laura Gatti, Anna Bersano
Summary: Thanks to improved knowledge and diagnostic techniques, the clinical spectrum of cerebral amyloid angiopathy (CAA) is now broader and includes sporadic CAA, hereditary CAA, CAA-related inflammation (CAA-ri), and iatrogenic CAA (iCAA). CAA-ri, an aggressive subtype with vascular inflammation, has gained attention due to the efficacy of anti-inflammatory drugs. There is increasing scientific interest in an atypical variant of iCAA. This brief review aims to increase awareness and understanding of these rare forms of CAA.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Cell Biology
Wenjun Deng, Shuzhen Guo, Susanne J. van Veluw, Zhanyang Yu, Su Jing Chan, Hajime Takase, Ken Arai, MingMing Ning, Steven M. Greenberg, Eng H. Lo, Brian J. Bacskai
Summary: This study explores the involvement of vascular dysfunction in the cognitive impairment of Alzheimer's disease and cerebral amyloid angiopathy. The findings suggest that the accumulation of beta-amyloid in the brain blood vessel walls disrupts neurovascular coupling, activates the cell cycle in quiescent endothelial cells, and enhances inflammation, contributing to the vascular pathology of these diseases.
Article
Clinical Neurology
Derrick N. Okine, David S. Knopman, Thomas H. Mosley, Dean F. Wong, Michelle C. Johansen, Keenan A. Walker, Clifford R. Jack Jr, Kejal Kantarci, James R. Pike, Jonathan Graff-Radford, Rebecca F. Gottesman
Summary: This study evaluated the association between CMB patterns and cerebral A beta deposition and found that a lobar-only pattern of CMBs or superficial siderosis is most strongly associated with brain A beta, while a mixed CMB pattern does not have an elevated risk.
Review
Clinical Neurology
Mariagiovanna Cozza, Lucia Amadori, Virginia Boccardi
Summary: Cerebral Amyloid Angiopathy (CAA) is a neurological disorder characterized by the deposition of amyloid plaques in the walls of cerebral blood vessels. This article provides insights into its pathogenesis, diagnosis, and treatment options. Accurate diagnosis of CAA is crucial for its management, and experimental treatments targeting amyloid beta clearance and anti-inflammatory approaches offer hope for future therapeutic advancements.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
E. Ruifang, Yaling Shi, Weiwei Wang, Ming Qi
Summary: This study investigated the mechanism by which callistephin mitigates the formation of A beta aggregation and associated CAA, showing that callistephin inhibits A beta fibrillization and reduces cytotoxicity against CVSMCs. These findings suggest potential protective effects of callistephin against CAA through regulation of membrane leakage and downregulation of inflammatory proteins.
ARABIAN JOURNAL OF CHEMISTRY
(2022)
Article
Clinical Neurology
Joan Marti-Fabregas, Pol G. Camps-Renom, Jonathan G. Best, Anna Ramos-Pachon, Marina Guasch-Jimenez, Alejandro Martinez-Domeno, Daniel M. Guisado-Alonso, Beatriz M. Gomez-Anson, Gareth Ambler, Duncan Wilson, Keon-Joo Lee, Jae-Sung Lim, Hee-Joon Bae, Masayuki Shiozawa, Masatoshi Koga, Kazunori G. Toyoda, Michael G. Hennerici, Hugues Chabriat, Eric Jouvent, Debbie Yuen Kwun Wong, Henry Mak, Kui Kai Lau, Young Dae Kim, Tae-Jin Song, Ji-Hoe Heo, Sebastian Eppinger, Thomas Gattringer, Ender Uysal, Derya Selcuk Demirelli, Natan Bornstein, Einor Ben Assayag, Hen A. Hallevi, Jeremy A. Molad, Masashi Nishihara, Jun Tanaka, Hideo Hara, Yusuke B. Yakushiji, Shelagh B. Coutts, Eric A. Smith, Alexandros A. Polymeris, Benjamin Wagner, David A. Seiffge, Philippe A. Lyrer, Nils T. Peters, Stefan T. Engelter, Rustam Al-Shahi Salman, Hans Rudolf Jager, Gregory Y. H. Lip, Martina Goeldlin, Leonidas Panos, Christopher Charles G. Karayiannis, Thanh G. K. Phan, Velandai K. Srikanth, Nicolas Christ, Sarah Gunkel, Felix W. Fluri, Thomas W. Leung, Yannie O. Y. Soo, Winnie Chu, Jill Abrigo, Carmen Barbato, Simone Browning, Robert Simister, Anne-Marie Mendyk, Regis Bordet, Saima Hilal, Bibek Gyanwali, Christopher Chen, Simon Jung, Dilek Necioglu Orken, David Werring, Luis Prats-Sanchez
Summary: This study aimed to investigate the risk of future cerebrovascular events in patients with ischemic stroke (IS) or transient ischemic attack (TIA) and cortical superficial siderosis (cSS), as well as the benefits and safety of antithrombotic drugs for secondary prevention. The study found that cSS was associated with an increased risk of stroke, and the risk of IS was higher than that of intracranial hemorrhage (ICrH) in patients receiving antiplatelet or anticoagulant treatment alone, while the risk of ICrH was higher than that of IS in patients receiving both treatments. Therefore, the study suggests that using antiplatelet or anticoagulant drugs alone is safe in patients with cSS, but combined antithrombotic therapy might be hazardous.
Review
Biochemistry & Molecular Biology
Michalis Michailidis, Despina Moraitou, Despina A. Tata, Kallirhoe Kalinderi, Theodora Papamitsou, Vasileios Papaliagkas
Summary: This review article discusses the shared pathophysiological connections between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM), emphasizing the role of insulin in the brain and the mechanistic interplay between the two diseases. The findings highlight the need for routine evaluation and treatment of cognitive impairment in T2DM patients and the evaluation of insulin levels or T2DM in AD patients. The hypothesis of AD as a type 3 diabetes is strongly supported.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Neurosciences
Claire Muller
Summary: Recently, there has been increased recognition of iatrogenic cerebral amyloid angiopathy (iCAA) cases globally. This case study examines the clinicoradiological features of a probable iCAA case in Australia, with extensive history documentation and MRI data spanning two decades. The study highlights the aggressive course and early disease manifestations of iCAA, providing insights for the more commonly seen sporadic cases.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Clinical Neurology
Audrey Low, Elijah Mak, Maura Malpetti, Luca Passamonti, Nicolas Nicastro, James D. Stefaniak, George Savulich, Leonidas Chouliaras, Li Su, James B. Rowe, Hugh S. Markus, John T. O'Brien
Summary: This study examined the relationship between SVD and neuroinflammation, revealing an association between microglial activation and the hypertensive arteriopathy subtype of SVD. The findings suggest that targeting neuroinflammation could be a novel therapeutic strategy for SVD.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2021)
Article
Biophysics
Luis Mauricio T. R. Lima, Luis Pena Icart
Summary: The discovery of insulin a century ago has led to a substantial increase in therapeutic polypeptides targeting diabetes and obesity. The focus is now on highly pure recombinant insulin and other peptide-based hormones and analogs. Proper formulation, storage, manipulation, and usage are required in order to avoid aggregation into high molecular weight products.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2022)
Article
Clinical Neurology
Andreas Charidimou, Gregoire Boulouis
Summary: This article conducted a meta-analysis to evaluate the value and accuracy of the Boston criteria in diagnosing probable sporadic cerebral amyloid angiopathy (CAA) patients. The results showed that the Boston criteria v.1.0 and v.1.5 have moderate-to-good diagnostic accuracy for probable CAA in symptomatic patients, with high specificity but low-to-moderate sensitivity.
Article
Clinical Neurology
Jennifer S. Rabin, Emma Nichols, Renaud La Joie, Kaitlin B. Casaletto, Priya Palta, Kristen Dams-O'Connor, Raj G. Kumar, Kristen M. George, Claudia L. Satizabal, Julie A. Schneider, Judy Pa, Adam M. Brickman
Summary: Accumulating data suggests that cerebrovascular disease contributes to the pathophysiology and progression of Alzheimer's disease. Cerebral amyloid angiopathy, characterized by the build-up of beta-amyloid in blood vessel walls, commonly co-occurs with Alzheimer's disease in the aging brain and increases the risk of dementia. This study found that cerebral amyloid angiopathy independently or interactively influences tau deposition and cognitive decline, and tau mediates the association between cerebral amyloid angiopathy and cognitive decline.
Article
Clinical Neurology
Ya Su, Jiayu Fu, Yanrong Zhang, Jiajie Xu, Qiang Dong, Xin Cheng
Summary: The study found visuospatial dysfunction in patients with cerebral amyloid angiopathy (CAA), especially in visual object perception impairment, which was associated with posterior white matter damage rather than global disease severity.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)